Tecfidera Approved in China to Treat Relapsing MS

Tecfidera Approved in China to Treat Relapsing MS

292146

Tecfidera Approved in China to Treat Relapsing MS

Tecfidera (dimethyl fumarate) was given the green light by health regulators in China to treat people with relapsing multiple sclerosis (MS) — clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. The National Medical Products Administration’s (NMPA) decision came through a priority review of clinical trial data for Tecfidera, an oral treatment developed and marketed by Biogen. “It is truly a milestone to bring this well-established treatment to China and be able to help people living…

You must be logged in to read/download the full post.